J. Knipper & Company Pharmaceutical Import Profile — United States (DGFT 2022–2026)

Name: J. Knipper & Company Pharmaceutical Import Records from India — 28 Products, $68.5M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

J. Knipper & Company — Pharmaceutical Importer Profile (2026) | 28 Products, $68.5M Trade | TransData Nexus

J. Knipper & Company

Pharmaceutical Importer · United States · Cardiovascular Focus · $68.5M Total Trade · DGFT Verified

J. Knipper & Company is a pharmaceutical importer based in United States with a total trade value of $68.5M across 28 products in 14 therapeutic categories. Based on 1,764 verified import shipments from Indian Customs (DGFT) records, J. Knipper & Company is the #1 buyer in 2 products including Fluorouracil, Theophylline. J. Knipper & Company sources from 1 verified Indian supplier, with Alembic Pharmaceuticals Limited accounting for 100.0% of imports.

J. Knipper & Company — Import Portfolio & Supplier Network

J. Knipper & Company import network — 28 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to J. Knipper & Company?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Alembic Pharmaceuticals Limited	$20.0M	808	100.0%

J. Knipper & Company sources from 1 verified Indian supplier across 415 distinct formulations. The sourcing is highly concentrated — Alembic Pharmaceuticals Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

Formulation	Value	Ships
Losartan 100mg_1000t_ap_us	$729.5K	16
Valsartan tabs USP 160MG 90t_ap	$401.6K	9
Celecoxib capsule 200	$373.0K	11
Azithromycin USP 250MG 3x1x6t bli	$370.7K	11
Tadalafil TAB USP 20MG 30t ap	$334.5K	12
Azithromycin tablets USP 250 MG TAB	$328.3K	8
Aripiprazole od USP 15MG, 3x10t, ap us	$300.0K	6
Losartan 50mg_1000t_ap_us	$270.5K	7
Amlodi valsarta 5 & 160MG USP 90t	$260.3K	6
Fluoxetine cap USP 40	$221.6K	6
Celecoxib capsule 200	$207.6K	6
Adapalene gel, USP 0.3% (45g pump)	$200.0K	4
Timolol mal opht gel form soln 0.5% 5ML	$200.0K	4
Asenapine sublingual tab10mg_6x10t_ap_us	$198.7K	5
Amlodi valsarta 5 & 160MG USP 30t	$198.6K	6

Import Portfolio — Top 28 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Celecoxib	Analgesics & Antipyretics	$9.8M	338	3.2%	5
2	Losartan	Cardiovascular	$8.7M	194	1.5%	7
3	Valsartan	Cardiovascular	$6.7M	151	2.2%	10
4	Doxycycline	Antibiotics	$6.7M	133	2.5%	4
5	Azithromycin	Antibiotics	$4.4M	107	1.7%	7
6	Fluoxetine	CNS & Psychiatric	$4.0M	163	1.1%	9
7	Clonazepam	CNS & Psychiatric	$3.9M	105	1.4%	2
8	Ketorolac	Analgesics & Antipyretics	$3.5M	71	1.3%	8
9	Famotidine	Gastrointestinal	$3.2M	77	5.8%	2
10	Febuxostat	Lipid & Metabolism	$2.8M	56	2.2%	4
11	Metronidazole	Advanced Antibiotics	$2.5M	49	0.8%	4
12	Paclitaxel	Oncology	$2.2M	45	2.2%	4
13	Fluorouracil	Oncology	$1.9M	39	8.1%	1
14	Oseltamivir	Antivirals	$1.6M	32	0.8%	6
15	Dapsone	Antimalarial & Antiparasitic	$1.0M	20	2.2%	5
16	Cyclophosphamide	Oncology	$805.9K	28	2.4%	4
17	Diclofenac	Analgesics & Antipyretics	$700.0K	14	0.2%	16
18	Nystatin	Antifungals	$676.7K	48	0.8%	12
19	Docetaxel	Oncology	$600.0K	12	1.5%	5
20	Methotrexate	Immunosuppressants	$600.0K	12	1.1%	7
21	Theophylline	Respiratory	$450.0K	9	1.3%	1
22	Itraconazole	Antifungals	$428.8K	26	1.6%	14
23	Moxifloxacin	Advanced Antibiotics	$381.1K	12	1.2%	10
24	Diltiazem	Cardiovascular	$250.0K	5	1.4%	10
25	Fulvestrant	Advanced Oncology	$250.0K	5	1.7%	2
26	Tobramycin	Antibiotics	$250.0K	5	0.6%	17
27	Erlotinib	Advanced Oncology	$106.9K	6	4.0%	4
28	Diazepam	CNS & Psychiatric	$100.0K	2	1.3%	4

J. Knipper & Company imports 28 pharmaceutical products across 14 categories into United States totaling $68.5M. The company is the #1 buyer for 2 products: Fluorouracil, Theophylline.

J. Knipper & Company — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

J. Knipper & Company, Inc., established in 1986 and headquartered in Lakewood, New Jersey, is a prominent healthcare solutions provider specializing in the pharmaceutical, biotechnology, and medical device sectors. The company offers a comprehensive suite of services, including sample management, third-party logistics (3PL), and specialty pharmacy solutions. Notably, Knipper is recognized as the largest provider of sample management services in the United States.

In 2020, Knipper expanded its capabilities by acquiring Eagle Pharmacy, a full-service, direct-to-patient pharmacy. This strategic acquisition enhanced Knipper's ability to deliver patient assistance programs and direct-to-patient services, further solidifying its position in the healthcare logistics landscape.

2Distribution Network

Knipper operates an extensive distribution network across the United States, featuring multiple facilities designed to meet diverse logistical needs. A significant expansion occurred in 2021 with the completion of a 150,000-square-foot addition to their Charlestown, Indiana, facility, which included refrigerated and freezer storage capabilities. Additionally, the company has a 312,600-square-foot facility in Jeffersonville, Indiana, equipped with FDA and DEA certifications, temperature-controlled storage, and integrated conveyor systems to streamline operations.

3Industry Role

J. Knipper & Company serves as a multifaceted entity within the U.S. pharmaceutical supply chain. It functions as a primary wholesaler, distributing pharmaceutical products to various stakeholders, including healthcare providers and pharmacies. Through its Knipper 3PL division, the company offers third-party logistics services, encompassing warehousing, distribution, and compliance solutions. Furthermore, Knipper's acquisition of Eagle Pharmacy in 2020 enabled it to provide direct-to-patient services, enhancing its role in the pharmaceutical distribution ecosystem.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — J. Knipper & Company

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

J. Knipper & Company's sourcing strategy exhibits a high degree of concentration, with a total import value of $68.5 million from India, accounting for 1,764 shipments of 28 products across 14 therapeutic categories. The top five imported products—Celecoxib, Losartan, Valsartan, Doxycycline, and Azithromycin—collectively represent 53% of the total import value. This significant concentration suggests a strategic partnership with a single supplier, Alembic Pharmaceuticals Limited, which accounts for the entire import volume from India. While such a focused sourcing approach can lead to favorable terms and streamlined logistics, it also introduces risks associated with supplier dependency, including potential disruptions in supply continuity and pricing volatility.

2Supply Chain Resilience

The resilience of J. Knipper & Company's supply chain is closely tied to its exclusive relationship with Alembic Pharmaceuticals Limited. This singular sourcing model may pose challenges in mitigating supply chain disruptions, as any operational issues at Alembic could directly impact Knipper's ability to meet market demands. The limited diversification in suppliers and formulations imported indicates a potential vulnerability to supply chain interruptions. To enhance resilience, Knipper might consider diversifying its supplier base and expanding the range of formulations sourced, thereby reducing dependency on a single supplier and improving the robustness of its supply chain.

Importing Pharmaceuticals into United States — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United States

1Regulatory Authority & Framework

In the United States, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing the importation of pharmaceutical products. The Federal Food, Drug, and Cosmetic Act (FD&C Act) establishes the legal framework governing the importation of drugs, ensuring they meet standards for safety, efficacy, and quality. The FDA's Regulatory Procedures Manual Chapter 9 outlines the import operations and actions required for compliance.

2Import Licensing & GMP

Importers of pharmaceutical products into the United States must adhere to specific licensing requirements, including obtaining an FDA registration as an importer. Additionally, imported drugs must comply with Good Manufacturing Practice (GMP) standards, which are internationally recognized and include EU GMP, WHO GMP, and PIC/S certifications. These certifications ensure that manufacturing processes meet stringent quality control measures. Wholesale distributors must also obtain appropriate state-level licenses to operate legally within their jurisdictions.

3Quality & Labeling

J. Knipper & Company — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

J. Knipper & Company's focus on importing products in the cardiovascular, analgesics & antipyretics, and antibiotics categories aligns with prevalent health concerns in the United States. Cardiovascular diseases remain a leading cause of morbidity and mortality, driving demand for related medications. Analgesics and antipyretics are consistently sought after for pain management and fever reduction. Antibiotics are essential in treating various infections, maintaining their demand in the healthcare market. This strategic product selection positions Knipper to address critical therapeutic needs effectively.

2Sourcing Profile

J. Knipper & Company's sourcing strategy emphasizes generic drug imports, focusing on finished pharmaceutical formulations such as tablets, capsules, syrups, and injections. India's robust pharmaceutical manufacturing sector, known for its compliance with international GMP standards, makes it a preferred source for these products. By importing finished formulations, Knipper can offer a diverse product portfolio without the complexities associated with raw material sourcing and API manufacturing.

3Market Positioning

Seller's Guide — How to Become a Supplier to J. Knipper & Company

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to engage with J. Knipper & Company by offering alternative products or formulations that complement Knipper's existing portfolio. Diversifying the supplier base can mitigate risks associated with single-source dependency and enhance supply chain resilience. Suppliers should focus on products that align with Knipper's therapeutic focus and comply with FDA regulations to meet the stringent quality standards required for the U.S. market.

2Requirements & Qualifications

Indian exporters aiming to supply J. Knipper & Company and the U.S. market must obtain FDA registration as drug manufacturers and comply with applicable GMP standards, such as EU GMP, WHO GMP, or PIC/S certifications. Products must meet FDA labeling requirements, including accurate and informative labeling in English. Additionally, exporters should ensure that their products are serialized in accordance with DSCSA mandates to facilitate traceability and enhance supply chain security.

3How to Approach

Frequently Asked Questions — J. Knipper & Company

What products does J. Knipper & Company import from India?

J. Knipper & Company imports 28 pharmaceutical products across 14 categories. Top imports: Celecoxib ($9.8M), Losartan ($8.7M), Valsartan ($6.7M), Doxycycline ($6.7M), Azithromycin ($4.4M).

Who supplies pharmaceuticals to J. Knipper & Company from India?

J. Knipper & Company sources from 1 verified Indian suppliers. The primary supplier is Alembic Pharmaceuticals Limited (100.0% of imports, $20.0M).

What is J. Knipper & Company's total pharmaceutical import value?

J. Knipper & Company's total pharmaceutical import value from India is $68.5M, based on 1,764 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does J. Knipper & Company focus on?

J. Knipper & Company imports across 14 categories. The largest: Cardiovascular (22.9%), Analgesics & Antipyretics (20.5%), Antibiotics (16.6%).

Get Full J. Knipper & Company Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 5 company name variants from customs records. For current shipment-level data, contact TransData Nexus.